Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) has been invited to present at the prestigious DCNY Summit, taking place in Washington, DC on September 18, 2025, and in New York on September 22, 2025. The summit, co-hosted by the Alliance Indus Foundation and various international partners, brings together policymakers, investors, and corporate leaders.
During the event, Hemogenyx will showcase its clinical progress, including updates on its Phase I clinical trial of CAR-T cell therapy for acute myeloid leukemia (AML). The company will have the opportunity to engage with key stakeholders and potential investors, as the summit has previously helped participants secure significant growth capital.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) è stata invitata a presentare al prestigioso DCNY Summit, che si svolgerà a Washington, DC il 18 settembre 2025 e a New York il 22 settembre 2025. Il summit, co-organizzato dalla Alliance Indus Foundation e da vari partner internazionali, riunisce responsabili politici, investitori e dirigenti aziendali.
Durante l'evento Hemogenyx illustrerà i progressi clinici raggiunti, comprese le novità sul trial clinico di Fase I della terapia CAR-T per la leucemia mieloide acuta (AML). La società avrà l'opportunità di confrontarsi con stakeholder chiave e potenziali investitori: in passato il summit ha aiutato i partecipanti a ottenere capitali di crescita rilevanti.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) ha sido invitada a presentar en el prestigioso DCNY Summit, que se celebrará en Washington, DC el 18 de septiembre de 2025 y en Nueva York el 22 de septiembre de 2025. La cumbre, coorganizada por la Alliance Indus Foundation y varios socios internacionales, reúne a responsables políticos, inversores y líderes empresariales.
Durante el evento, Hemogenyx mostrará sus avances clínicos, incluyendo actualizaciones sobre su ensayo clínico de Fase I de la terapia CAR-T para la leucemia mieloide aguda (AML). La compañía tendrá la oportunidad de conectarse con los principales interesados y posibles inversores; en ediciones anteriores la cumbre ha ayudado a participantes a asegurar importantes fondos de crecimiento.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF)가 권위 있는 DCNY Summit에 초청되어 2025년 9월 18일 워싱턴 DC와 2025년 9월 22일 뉴욕에서 발표를 진행합니다. 이 서밋은 Alliance Indus Foundation과 여러 국제 파트너가 공동 주최하며 정책 입안자, 투자자 및 기업 리더들을 한자리에 모읍니다.
행사 기간 동안 Hemogenyx는 급성 골수성 백혈병(AML) 대상 CAR-T 세포치료의 1상 임상시험 등 임상 진행 상황을 소개할 예정입니다. 회사는 주요 이해관계자 및 잠재 투자자들과 교류할 기회를 갖게 될 것이며, 과거 이 서밋은 참가자들이 상당한 성장 자금을 유치하는 데 도움을 준 바 있습니다.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) a été invitée à présenter au prestigieux DCNY Summit, qui se tiendra à Washington, DC le 18 septembre 2025 et à New York le 22 septembre 2025. Le sommet, coparrainé par la Alliance Indus Foundation et plusieurs partenaires internationaux, rassemble des décideurs politiques, des investisseurs et des dirigeants d'entreprise.
Lors de l'événement, Hemogenyx présentera ses avancées cliniques, y compris des mises à jour sur son essai clinique de phase I de thérapie CAR‑T pour la leucémie myéloïde aiguë (LMA). La société aura l'occasion d'échanger avec des parties prenantes clés et des investisseurs potentiels ; par le passé, le sommet a aidé des participants à obtenir des capitaux de croissance importants.
Hemogenyx Pharmaceuticals (OTCQB:HOPHF) wurde eingeladen, auf dem renommierten DCNY Summit zu präsentieren, das am 18. September 2025 in Washington, DC und am 22. September 2025 in New York stattfindet. Der Gipfel, der von der Alliance Indus Foundation und verschiedenen internationalen Partnern mitveranstaltet wird, bringt politische Entscheidungsträger, Investoren und Unternehmensleiter zusammen.
Während der Veranstaltung wird Hemogenyx seine klinischen Fortschritte vorstellen, einschließlich Updates zu seiner Phase‑I‑Studie zur CAR‑T‑Zelltherapie bei akuter myeloischer Leukämie (AML). Das Unternehmen erhält die Gelegenheit, mit wichtigen Akteuren und potenziellen Investoren in Kontakt zu treten; in der Vergangenheit hat der Gipfel Teilnehmern geholfen, bedeutende Wachstumskapitalien zu sichern.
- None.
- None.
Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit
LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company has been invited to participate and present at the upcoming DCNY Summit, taking place in Washington, DC on 18 September 2025 and in New York on 22 September 2025.
The DCNY Summit is co-hosted by the Alliance Indus Foundation, together with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other international partners, and is designed as a high-level forum connecting Washington, DC and New York to bring together policymakers, investors, corporate leaders, and innovators.
Hemogenyx will present its clinical progress and pipeline as part of the Summit's curated company showcase. Previous Summit participants have successfully secured significant growth capital, underscoring the Summit's reputation as a catalyst for financing and partnerships.
Participation in the DCNY Summit provides Hemogenyx with a valuable platform to:
Highlight recent clinical milestones, including the ongoing Phase I clinical trial of its lead CAR-T cell therapy for acute myeloid leukemia (AML);
Showcase the Company's broader therapeutic pipeline to an audience of influential stakeholders;
Engage directly with investors, collaborators, and decision-makers at the intersection of science, healthcare, and finance.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are honored to have been invited to present Hemogenyx at the DCNY Summit. This prestigious event convenes a remarkable group of global investors, corporate leaders, and policymakers, and provides us with a unique opportunity to highlight our progress and to engage with those who can help accelerate our mission to transform the treatment of cancer."
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About DCNY Summit
The DCNY Summit (https://dcnysummit.org) is an annual high-level forum connecting Washington, DC and New York to bring together policymakers, corporate leaders, investors, and innovators. It is co-hosted by the Alliance Indus Foundation in partnership with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other global organizations. The Summit serves as a platform for showcasing transformative companies, fostering international collaboration, and catalyzing financing and innovation across life sciences, healthcare, and technology sectors.
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
When and where will Hemogenyx Pharmaceuticals (HOPHF) present at the DCNY Summit 2025?
What will Hemogenyx Pharmaceuticals showcase at the DCNY Summit 2025?
Who are the co-hosts of the DCNY Summit 2025?
What is the significance of Hemogenyx's participation in the DCNY Summit?
